And then it got me.” A handful of decades and an MIT physics doctorate later, Tan is the chief science officer (CSO) of ...

An ambitious form of climate modelling aims to pin the blame for disasters – from floods to heatwaves – on specific companies ...

Ripples spreading across a calm lake after raindrops fall—and the way ripples from different drops overlap and travel outward ...

His job is to reimagine the future of drugmaking using that similarly trendy branch of computer science, artificial ...

Stewart Cheifet, the television producer and host who documented the personal computer revolution for nearly two decades on ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...